2025
Emergency Department Implementation of a Multimodal Electronic Health Record–Integrated Clinical Intervention for High-Sensitivity Troponin Testing Increases Diagnostic Efficiency
Sangal R, Iscoe M, Rothenberg C, Possick S, Taylor R, Safdar B, Desai N, Rhodes D, Venkatesh A. Emergency Department Implementation of a Multimodal Electronic Health Record–Integrated Clinical Intervention for High-Sensitivity Troponin Testing Increases Diagnostic Efficiency. Journal Of The American College Of Emergency Physicians Open 2025, 6: 100202. DOI: 10.1016/j.acepjo.2025.100202.Peer-Reviewed Original ResearchEmergency departmentAcute myocardial infarction diagnosisTroponin testingED dischargeMyocardial infarction diagnosisAssociated with lower oddsAccelerated diagnostic protocolPhysician practice variationAcute coronary syndromeInfarction diagnosisChest pain evaluationMultivariate logistic regressionSuspected acute coronary syndromePostintervention periodDownstream testingPhysician practicesPreintervention periodED dispositionLower oddsCoronary syndromeDecreased oddsIncreased oddsPractice variationED patientsHs-cTnTTicagrelor Versus Prasugrel in Acute Coronary Syndrome: Real-World Treatment and Safety
Bahouth F, Chutko B, Sholy H, Hassanain S, Zaid G, Radzishevsky E, Fahmwai I, Hamoud M, Samnia N, Khoury J, Dobrecky-Mery I. Ticagrelor Versus Prasugrel in Acute Coronary Syndrome: Real-World Treatment and Safety. Medicines 2025, 12: 13. PMID: 40407605, PMCID: PMC12194868, DOI: 10.3390/medicines12020013.Peer-Reviewed Original ResearchAcute coronary syndromeCoronary syndromeAntiplatelet drugsCardiovascular deathComposite endpoint of cardiovascular deathAdmitted with acute coronary syndromeEndpoint of cardiovascular deathTreated with ticagrelorTreated with prasugrelSingle-center studyRetrospective observational studyRecurrent cardiac eventsDual antiplatelet drugsReal-world treatmentPercutaneous coronary interventionBARC classificationSignificant bleedingPrasugrel groupPrimary endpointP2Y12 inhibitorsNo significant differenceACS patientsCardiac eventsComposite endpointPrasugrelANTITHROMBOTIC STRATEGY FOR PATIENTS WITH CONCOMITANT CHRONIC CORONARY SYNDROME AND ATRIAL FIBRILLATION: A POOLED ANALYSIS OF 3 RANDOMIZED-CONTROLLED TRIALS
Chi K, Lee P, Pazooki P, Kumar S, Borkowski P, Hussain A, Nanna M. ANTITHROMBOTIC STRATEGY FOR PATIENTS WITH CONCOMITANT CHRONIC CORONARY SYNDROME AND ATRIAL FIBRILLATION: A POOLED ANALYSIS OF 3 RANDOMIZED-CONTROLLED TRIALS. Journal Of The American College Of Cardiology 2025, 85: 1904. DOI: 10.1016/s0735-1097(25)02388-5.Peer-Reviewed Original ResearchDrug-Coated Balloons for Coronary Artery Disease: From Theory to Practice
Moumneh M, Jamil Y, Nanna M, Damluji A. Drug-Coated Balloons for Coronary Artery Disease: From Theory to Practice. Current Treatment Options In Cardiovascular Medicine 2025, 27: 28. DOI: 10.1007/s11936-025-01084-4.Peer-Reviewed Original ResearchDrug-Coated BalloonCoronary artery diseasePercutaneous coronary interventionArtery diseaseIn-stent stenosisAcute coronary syndromeNovel DCBEffective drug deliveryIn-stent restenosisBleeding riskDrug-eluting stentsIncreased bleedingPatient selectionLarge-vessel diseaseStandard treatmentCoronary syndromeClinical indicationsDiabetes mellitusReduce complicationsReviewThe purposeCoronary interventionDe-novo small vessel diseaseClinical casesLesion preparationConsensus groupCombined atherectomy and intravascular lithotripsy in calcified coronary lesions: a meta-analysis.
Singh S, Garg A, Tantry U, Bliden K, Gurbel P, Kochar A, Nanna M, Damluji A. Combined atherectomy and intravascular lithotripsy in calcified coronary lesions: a meta-analysis. Journal Of Invasive Cardiology 2025 PMID: 39993271, DOI: 10.25270/jic/24.00312.Peer-Reviewed Original ResearchCalcified coronary lesionsProcedural success rateCoronary lesionsIntravascular lithotripsyCoronary perforationRisk of procedural complicationsRisk of adverse CV eventsAcute procedural successSuccess rateAcute coronary syndromeAdverse CV eventsTarget vessel revascularizationSeverely calcified coronary lesionsRandom-effects modelTreatment of severely calcified coronary lesionsPeriprocedural complicationsPooled proportionProcedural complicationsProcedural successCV deathCoronary syndromeCV eventsFollow-upProcedural outcomesCV outcomesPrevalence and prognostic impact of ST-segment elevation in lead aVR among patients with cardiac arrest
Banna S, Schenck C, Kim N, Ali T, Gilmore E, Greer D, Beekman R, Miller P. Prevalence and prognostic impact of ST-segment elevation in lead aVR among patients with cardiac arrest. European Heart Journal Acute Cardiovascular Care 2025, 14: 232-236. PMID: 39873390, DOI: 10.1093/ehjacc/zuaf018.Peer-Reviewed Original ResearchOut-of-hospital cardiac arrestAssociated with higher in-hospital mortalityHigher In-Hospital MortalityST-segment elevationIn-Hospital MortalityReturn of spontaneous circulationCardiac arrestShockable rhythmLead aVRPoor neurological outcomeAcute coronary syndromeMultivariate logistic regressionPrognostic impactPost-ROSCPrognostic significanceSpontaneous circulationCA patientsNeurological outcomeCoronary syndromeIdentified patientsMultivariable adjustmentMain diseasePatientsCA survivorsArrest characteristics
2024
Short Versus One-Year Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: an Updated Meta-Analysis
Joseph M, Krishna M, Ezenna C, Pereira V, Ismayl M, Nanna M, Bangalore S, Goldsweig A. Short Versus One-Year Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: an Updated Meta-Analysis. The American Journal Of Cardiology 2024, 237: 17-28. PMID: 39577682, DOI: 10.1016/j.amjcard.2024.10.038.Peer-Reviewed Original ResearchPost-percutaneous coronary interventionAcute coronary syndromeDrug-eluting stentsPercutaneous coronary interventionCoronary interventionAcute coronary syndrome cohortCochrane CENTRAL databasesShortening DAPT durationMonths post-percutaneous coronary interventionClopidogrel subgroupRandomized Controlled TrialsNo significant differenceCoronary syndromeMonotherapyTicagrelor monotherapyDAPT durationShorter DAPTBleedingStent thrombosisP2Y12iMyocardial infarctionControlled TrialsSubgroup interactionsDAPTMeta-analysisEffect of apixaban versus vitamin K antagonist and aspirin versus placebo on days alive and out of hospital: An analysis from AUGUSTUS
Fanaroff A, Vora A, Wojdyla D, Mehran R, Granger C, Goodman S, Aronson R, Windecker S, Alexander J, Lopes R. Effect of apixaban versus vitamin K antagonist and aspirin versus placebo on days alive and out of hospital: An analysis from AUGUSTUS. American Heart Journal 2024, 280: 60-69. PMID: 39557109, DOI: 10.1016/j.ahj.2024.11.005.Peer-Reviewed Original ResearchConceptsAcute coronary syndromeTime-to-event analysisAtrial fibrillationCoronary syndromeClinical trialsEffect of antithrombotic therapyVitamin K antagonistsProportion of patientsRobust variance estimationRandomized clinical trialsClinical trial endpointsPercutaneous coronary interventionK antagonistsAntithrombotic therapyPoisson regressionTreatment armsFollow-upIschemic eventsPlaceboRate ratiosAntithrombotic agentsTrial endpointsWarfarinCoronary interventionIntervention methodsInvasive Versus Conservative Strategy in Older Adults ≥75 Years of Age With Non-ST-segment-Elevation Acute Coronary Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Rout A, Moumneh M, Kalra K, Singh S, Garg A, Kunadian V, Biscaglia S, Alkhouli M, Rymer J, Batchelor W, Nanna M, Damluji A. Invasive Versus Conservative Strategy in Older Adults ≥75 Years of Age With Non-ST-segment-Elevation Acute Coronary Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal Of The American Heart Association 2024, 13: e036151. PMID: 39494560, PMCID: PMC11935716, DOI: 10.1161/jaha.124.036151.Peer-Reviewed Original ResearchConceptsNon-ST segment elevation acute coronary syndromeAcute coronary syndromeComposite of deathBurden of geriatric conditionsRandomized Controlled TrialsCoronary syndromeMyocardial infarctionYears of ageInvasive strategyOlder adultsControlled TrialsGeriatric conditionsOlder patientsCardiovascular deathOdds ratioMeta-analysis of randomized controlled trialsNon-ST segment elevationSecondary end pointsMeta-analysisFixed effects meta-analysisAll-cause deathEffects meta-analysisYounger patientsFollow-upDecreased riskMilvexian: evaluating the factor XIa inhibitor for the treatment of acute coronary syndrome
Tantry U, Raghavakurup L, Becker R, Singh S, Bliden K, Gurbel P. Milvexian: evaluating the factor XIa inhibitor for the treatment of acute coronary syndrome. Expert Opinion On Pharmacotherapy 2024, 25: 1271-1280. PMID: 39072402, DOI: 10.1080/14656566.2024.2385062.Peer-Reviewed Original ResearchConceptsAcute coronary syndromeCoronary syndromeElevated risk of bleedingPathological thrombosisTreatment of acute coronary syndromesClinical thrombotic eventsPhysiological hemostasisRisk of bleedingPrevention of thrombosisFXIa inhibitorsBleeding riskReceptor blockersThrombotic eventsAntiplatelet therapyPlatelet antagonistsAntithrombotic efficacyFXIa inhibitionThrombosisExperimental thrombosisPatientsElevated riskLiterature searchAnticoagulationLarge-scale studiesFXIaIn-hospital outcomes and postdischarge mortality in patients with acute coronary syndrome and atrial fibrillation
Saleh M, Coleman K, Fishbein J, Gandomi A, Yang B, Kossack A, Varrias D, Jauhar R, Lasic Z, Kim M, Mihelis E, Ismail H, Sugeng L, Singh V, Epstein L, Kuvin J, Mountantonakis S. In-hospital outcomes and postdischarge mortality in patients with acute coronary syndrome and atrial fibrillation. Heart Rhythm 2024, 21: 1658-1668. PMID: 38823670, DOI: 10.1016/j.hrthm.2024.05.045.Peer-Reviewed Original ResearchConceptsAcute coronary syndromePostdischarge mortalityAtrial fibrillationIn-Hospital OutcomesPostdischarge adverse outcomesOral anticoagulantsPatients admitted with acute coronary syndromeNorthwell Health hospitalsCoronary syndromeAdverse outcomesRisk of in-hospitalIntroduction of novel oral anticoagulantsIncreased risk of in-hospitalAcute coronary syndrome patientsManagement of acute coronary syndromesConcomitant atrial fibrillationNovel oral anticoagulantsHealth HospitalIndependent risk factorHierarchical generalized linear mixed modelsLinear mixed modelsIncidence of AFIn-Hospital MortalityMarginal Cox regression modelsIn-Hospital BleedingMachine learning prediction of one-year mortality after percutaneous coronary intervention in acute coronary syndrome patients
Hosseini K, Behnoush A, Khalaji A, Etemadi A, Soleimani H, Pasebani Y, Jenab Y, Masoudkabir F, Tajdini M, Mehrani M, Nanna M. Machine learning prediction of one-year mortality after percutaneous coronary intervention in acute coronary syndrome patients. International Journal Of Cardiology 2024, 409: 132191. PMID: 38777044, DOI: 10.1016/j.ijcard.2024.132191.Peer-Reviewed Original ResearchConceptsPercutaneous coronary interventionLogistic regressionPost-PCI mortalityPrediction of one-year mortalityCoronary interventionPrediction of 1-year mortalityBody mass indexAcute coronary syndrome patientsOne-year mortalityIndividual-level assessmentsReceiver operating characteristic curveAcute coronary syndromeCoronary syndrome patientsTehran Heart CenterRates of comorbiditiesMass indexHigher ageSyndrome patientsCoronary syndromeHeart CenterFollow-upLipid profileU-shaped correlationPatientsCharacteristic curveThe foundation for investigating factor XI as a target for inhibition in human cardiovascular disease
Ali A, Becker R. The foundation for investigating factor XI as a target for inhibition in human cardiovascular disease. Journal Of Thrombosis And Thrombolysis 2024, 57: 1283-1296. PMID: 38662114, PMCID: PMC11645312, DOI: 10.1007/s11239-024-02985-0.Peer-Reviewed Original ResearchConceptsCardiovascular diseaseCoronary syndromeChronic coronary syndromeFactor XIManagement of patientsSusceptible to pharmacological inhibitionAcute coronary syndromeHuman cardiovascular diseaseAnticoagulant therapyImmune dysregulationSystemic inflammationAtrial fibrillationClinical trialsPharmacological inhibitionTargeted drugsThrombosisIschemic strokeReparative capabilitiesPhenotypic expressionEnvironmental triggersOxidative stressDay-to-day patient careMolecular eventsSyndromeDiseaseDuration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-analysis
Park D, Hu J, Campbell G, Goldwag K, Kelsey M, Altin S, Gallegos-Kattán C, Nanna M. Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-analysis. Journal Of The Society For Cardiovascular Angiography & Interventions 2024, 3: 101859. PMID: 39131993, PMCID: PMC11307649, DOI: 10.1016/j.jscai.2024.101859.Peer-Reviewed Original ResearchMonths of DAPTDuration of dual antiplatelet therapyNet adverse clinical eventsType 2 diabetes mellitusDual antiplatelet therapyAcute coronary syndromeRandomized Controlled TrialsSensitivity analysis of trialsPercutaneous coronary interventionCoronary interventionNo significant differenceAntiplatelet therapyAnalysis of trialsCoronary syndromeControlled TrialsMeta-analysis of patientsStent thrombosisMeta-analysisDAPT durationClinicians greater flexibilityStudy-level meta-analysisOptimal duration of dual antiplatelet therapyHigher risk of adverse eventsPostpercutaneous coronary interventionRisk of adverse eventsClinical Interpretation of Serum Troponin in the Era of High-Sensitivity Testing
Maayah M, Grubman S, Allen S, Ye Z, Park D, Vemmou E, Gokhan I, Sun W, Possick S, Kwan J, Gandhi P, Hu J. Clinical Interpretation of Serum Troponin in the Era of High-Sensitivity Testing. Diagnostics 2024, 14: 503. PMID: 38472975, PMCID: PMC10930800, DOI: 10.3390/diagnostics14050503.Peer-Reviewed Original ResearchAcute coronary syndromeTn elevationCoronary syndromeTreatment of acute coronary syndromesNon-cardiac etiologyManagement of myocardial injuryEvaluation of patientsHigh-sensitivity assaySerum troponinHighly sensitive testPrognostic implicationsCardiac troponinMyocardial injuryPhysical examMyocardial ischemiaPoor specificityLaboratory dataClinical judgmentClinical interpretationTroponinSyndromeAnalytical sensitivityTN measurementsPresentationElevationTemporal biomarker concentration patterns during the early course of acute coronary syndrome
Eggers K, Batra G, Lindahl B, Lakic T, Lindbäck J, Budaj A, Cornel J, Giannitsis E, Katus H, Storey R, Becker R, Siegbahn A, Wallentin L. Temporal biomarker concentration patterns during the early course of acute coronary syndrome. Clinical Chemistry And Laboratory Medicine 2024, 62: 1167-1176. PMID: 38341860, DOI: 10.1515/cclm-2023-1253.Peer-Reviewed Original ResearchAcute coronary syndromeST-elevation myocardial infarctionSymptom onsetNSTE-ACSHs-cTnTGDF-15Concentrations of high-sensitivity cardiac troponin TNon-ST-elevation acute coronary syndromeHigh-sensitivity cardiac troponin TPro-B-type natriuretic peptideBiomarker patternsAcute coronary syndrome patientsGrowth differentiation factor 15Cardiac troponin TC-reactive proteinPathophysiological processesBiomarker concentrationsClinically useful informationPlatelet inhibitionNatriuretic peptideHs-cTnICoronary syndromeTroponin TEarly courseAssociated with timeLong-Term Percutaneous Coronary Intervention Outcomes in Chronic Versus Acute Coronary Syndromes (TARGET All Comers Trial)
Patel K, Lansky A, Kelbæk H, Xu B, van Royen N, Johnson T, Anderson R, Wijns W, Baumbach A, Investigators T. Long-Term Percutaneous Coronary Intervention Outcomes in Chronic Versus Acute Coronary Syndromes (TARGET All Comers Trial). The American Journal Of Cardiology 2024, 217: 94-101. PMID: 38350507, DOI: 10.1016/j.amjcard.2023.12.002.Peer-Reviewed Original ResearchChronic coronary syndromeAcute coronary syndromeTarget lesion failureSirolimus-eluting stentsEverolimus-eluting stentIschemia-driven target lesion revascularizationTarget lesion revascularizationCoronary syndromeDefinite/probable stent thrombosisStent thrombosisClinical presentationLesion revascularizationFIREHAWK stentAcute coronary syndrome presentationSpectrum of clinical presentationsAcute coronary syndrome populationXIENCE stentAcute coronary syndrome cohortLong-term PCI outcomesLong-term outcomesLong-term safetyOpen-labelPatient-oriented outcomesBaseline characteristicsAdverse eventsClinical Biochemistry of Serum Troponin
Gokhan I, Dong W, Grubman D, Mezue K, Yang D, Wang Y, Gandhi P, Kwan J, Hu J. Clinical Biochemistry of Serum Troponin. Diagnostics 2024, 14: 378. PMID: 38396417, PMCID: PMC10887818, DOI: 10.3390/diagnostics14040378.Peer-Reviewed Original ResearchAcute coronary syndromeFalse negative test resultsPoint of care assayInterpretation of serum levelsNegative test resultsTroponin complexChest painInterpretation of assay resultsSerum levelsClinical workupCoronary syndromeTn assaysMyocardial injuryTest characteristicsClinical settingCare assaysTroponinMeasurement assaysMolecular characteristicsPotential causesAssay resultsAssayMolecular structureFalse resultsConstituent proteins
2023
Digital Tools for Decision-Making in Coronary Artery Disease
Grubman D, Grubman S, See C, Breen T, Hu J, Altin S. Digital Tools for Decision-Making in Coronary Artery Disease. Current Treatment Options In Cardiovascular Medicine 2023, 25: 737-752. DOI: 10.1007/s11936-023-01022-2.Peer-Reviewed Original ResearchCoronary artery diseaseAcute coronary syndromePercutaneous coronary interventionArtery diseaseRisk stratificationDiagnosis of patientsCoronary syndromeCoronary interventionPoint of carePrimary preventionElectrocardiographic patternCatheterization labClinical uptakeRisk estimation modelCliniciansDiseaseSummaryThe developmentPatientsSyndromeStratificationDiagnosisTriageBiomarkersDigital aidsCareLong-term PCI outcomes in chronic versus acute coronary syndromes: 5-year results of the TARGET All Comers trial
Patel K, Lansky A, Kelbaek H, Xu B, Van Royen N, Johnson T, Anderson R, Wijns W, Baumbach A. Long-term PCI outcomes in chronic versus acute coronary syndromes: 5-year results of the TARGET All Comers trial. European Heart Journal 2023, 44: ehad655.1494. DOI: 10.1093/eurheartj/ehad655.1494.Peer-Reviewed Original ResearchAcute coronary syndromeChronic coronary syndromeProbable stent thrombosisCoronary syndromeStent thrombosisFIREHAWK stentLesion failureClinical presentationLong-term PCI outcomesPatient-oriented composite endpointTarget lesion revascularisationMajor adverse eventsLong-term outcomesLong-term safetyCCS cohortComer patientsID-TLRLesion revascularisationCCS patientsOpen labelAdverse eventsBaseline characteristicsACS cohortComposite endpointComers trial
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply